Invivyd (IVVD) shares fell past 12% in recent Tuesday trading after the biopharmaceutical company withdrew prior revenue guidance.
The company said the move was "due to recent growth headwind from US FDA's late-Q3 2024 warning on potential for substantially reduced activity of pemivibart through the Pemgarda Fact Sheet and other media based on contested, third-party, non-peer-reviewed, non-reproducible, virologic activity data from a non-pemivibart antibody."
The company previously guided to $150 million to $200 million in Pemgarda net product revenue in 2024 and expected to finish the year with $75 million or more in cash and cash equivalents.
Invivyd said its preliminary net product revenue now stands at $9.3 million for Q3 from Pemgarda, and it estimates it ended the quarter with about $107 million in cash and equivalents.
Price: 0.93, Change: -0.12, Percent Change: -11.06
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。